Metagenomi Therapeutics, Inc. (MGX) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Metagenomi Therapeutics, Inc. (MGX) closed at USD 0.86 on 2026-10-14, a change of -67.3 % over the past year, with a market capitalization of USD 31.93M.

Metagenomi Therapeutics, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Metagenomi Therapeutics, Inc. key figures

Previous close

USD 0.86 (2026-10-14)

1-year change

-67.3 %

Market cap

USD 31.93M

Enterprise value

USD -51.01M

P/E ratio (trailing)

-0.37

P/E ratio (forward)

-0.46

EPS (trailing)

-2.31

EPS (forward)

-1.84

PEG ratio

n/a

Price to book

0.28

Revenue growth

n/a

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

8.23

Employees

113

Analyst consensus (third-party)

strong_buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Metagenomi Therapeutics, Inc.

Metagenomi Therapeutics, Inc. an in vivo genome editing company, develops curative genetic medicines in the United States. The company's lead development program, MGX-001, is designed to provide curative, life-long protection from bleeding events and joint damage in adults and children with hemophilia. It has a collaboration agreement with Ionis Pharmaceuticals, Inc. for apolipoprotein C-III for the treatment of hyper triglyceridemia, transthyretin (TTR) for transthyretin amyloidosis, angiotensinogen (AGT) for refractory hypertension, and other programs. The company was formerly known as Metagenomi, Inc. and changed its name to Metagenomi Therapeutics, Inc. in January 2026. Metagenomi Therapeutics, Inc. was incorporated in 2016 and is headquartered in Emeryville, California.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Metagenomi Therapeutics, Inc. and compare it with other stocks.